In a proof-of-concept study published in Nature Biotechnology this week, the team demonstrated that it could enzymatically synthesize 10-mer oligonucleotides.
Isoma, which launched last year, will use the funds to develop and clinically validate a molecular test for stratifying glioblastoma patients.
The newly emerged Nashville Biosciences has the considerable genomics and bioinformatics resources of Vanderbilt behind it as it promotes new R&D techniques.
Armonica Technologies is looking to develop a nanochannel-based sequencing device that uses optical detection.
The startup aims to tap into the $60 billion probiotics industry by sequencing the microbiomes of athletes to identify bacteria that improve performance.
Researchers from the Netherlands Cancer Institute plan to spin out a company to use sequencing-based cellular network mapping to aid in drug development.
Inflammatix hopes to market an 18-gene panel that will be able to tell from a blood sample whether a hospitalized patient has a bacterial, viral, or no infection.
The firm is in the process of commercializing an open, optimizable, high-throughput library preparation instrument for single-cell transcriptome profiling.
The Harvard spinout is commercializing inDrop single-cell sequencing technology developed by Allon Klein.
The firm is considering separating the point-of-care and lab test arms of its business, delisting its shares, and buying back stock from shareholders.
Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.
The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.
Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.
In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.